|

WTX212A injection Clinical Trials

2 actively recruiting trials

Also known as: Erythrocyte-αPD-1 Antibody Conjugates, autologous red blood cell PD-1 inhibitor conjugate

Other2 trials

A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Phase 1
WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.